• News
AACR-2022 NI-3201 CD28 bispecific antibody platform

AACR-2022 NI-3201 CD28 bispecific antibody platform

AACR Annual Meeting 202- Sara Majocchi -


Decoding Cancer Complexity | Integrating Science | Transforming Patient Outcomes

The American Association for Cancer Research (AACR) will host its Annual Meeting April 8-13, 2022. Light Chain Bioscience is very pleased to have Sara Majocchi attend in-person.

Sara will be presenting a poster (#2884) describing Light Chain Bioscience's CD28-bispecific antibody platform.

“Optimized CD28 bispecific antibodies for targeted activation of T cells within the tumor microenvironment” will be exposed and presented on April 12 between 9:00 a.m -12:30 p.m.

Read poster - Poster section 37 [PDF]:

AACR 2022 NI 3201 CD28 bispecific antibody platform 3201


Ernest N. Morial Convention Center New Orleans, Louisiana

900 Convention Center Blvd, New Orleans, LA 70130, United States

First patient dosed with NILK-2301 in Phase I clinical trial

First-in-human trial of a CEACAM5xCD3 bispecific κλ body for solid cancer


Read more

LinkedIn